such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position...
are in final lead selection studies and manufacturing, in parallel, to prepare for the first-in-human study planned for 2026. "Our Phase 1 data for XmAb942 validate our design goals for a best-in-class anti-TL1A therapy, combining high potency with...
as an investor and board member, it’s an honor to step into the role of CEO as we prepare to enter clinical development in 2026 for our lead neuromuscular disease candidate which we plan to announce later this year. Creyon is committed to advancing...
innovation, and dedication – making a difference in the lives of almost 450 million patients annually. With Vision 2026, as part of the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and...
autoimmune diseases such as atopic dermatitis. Clinical results from these studies are anticipated by the end of 2026. About Artax Biopharma, Nck modulation, and AX-158 Artax Biopharma is a clinical-stage biotechnology company transforming the...
innovation, and dedication – making a difference in the lives of almost 450 million patients annually. With Vision 2026, as part of the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and...
$62.6 million as compared to $108.8 million as of December 31, 2023, which is expected to fund operations into at least 2H 2026 based on current plans. Total revenue for the quarter ended September 30, 2024, was $7.2 million, resulting from sales...
